Publications
Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A. 2013;110(2):E170-9.
. Integrated network analyses for functional genomic studies in cancer. Semin Cancer Biol. 2013;23(4):213-8.
. Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling. PLoS Comput Biol. 2013;9(2):e1002887.
. Models of signalling networks - what cell biologists can gain from them and give to them. J Cell Sci. 2013;126(Pt 9):1913-21.
. Molecular network analysis of phosphotyrosine and lipid metabolism in hepatic PTP1b deletion mice. Integr Biol (Camb). 2013;5(7):940-63.
. Multiplexed protease activity assay for low-volume clinical samples using droplet-based microfluidics and its application to endometriosis. J Am Chem Soc. 2013;135(5):1645-8.
. Network analysis of differential Ras isoform mutation effects on intestinal epithelial responses to TNF-α. Integr Biol (Camb). 2013;5(11):1355-65.
. Predicting cancer drug mechanisms of action using molecular network signatures. Mol Biosyst. 2013;9(7):1604-19.
. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal. 2013;6(287):ra66.
. Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks. Sci Signal. 2013;6(284):ra58.
. . Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov. 2014;4(2):166-74.
. .